Publication Name	World Journal of Meta-Analysis
Manuscript ID	82569
Country	India

Received	2022-12-23 08:16
Peer-Review Started	2022-12-23 08:20
To Make the First Decision
Return for Revision	2023-02-27 06:29
Revised	2023-03-11 10:05
Second Decision	2023-03-28 03:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-03-29 08:20
Articles in Press	2023-03-29 08:20
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-03-26 02:11
Typeset the Manuscript	2023-04-06 02:29
Publish the Manuscript Online	2023-04-14 06:38

ISSN	2308-3840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, General & Internal
Manuscript Type	Minireviews
Article Title	Lipocalin-2 as a biomarker for diabetic nephropathy
Manuscript Source	Invited Manuscript
All Author List	Kiran Dahiya, Praveen Prashant, Rakesh Dhankhar, Kumud Dhankhar, Sushil Kumar and Sonia Vashist
Funding Agency and Grant Number
Corresponding Author	Kiran Dahiya, MBBS, MD, Doctor, Professor, Department of Biochemistry, Pt BD Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India. kirandahiya_2002@yahoo.com
Key Words	Type 1 diabetes; Type 2 diabetes; Diabetic nephropathy; Lipocalin-2; Early biomarkers for kidney disease; Acute kidney injury
Core Tip	Diabetic nephropathy (DN) is a chronic complication of diabetes. The mainstay markers for kidney injury are a gradual decrease in glomerular filtration rate and microalbuminuria. Microalbuminuria appears late in DN; thus, new biomarkers are required. Different researchers highlighted the role of lipocalin-2 (NGAL) in the early detection of nephropathy before the appearance of microalbumin in urine. In this review, we briefly describe the role of NGAL in various diseases and cancers and detail its role as an early biomarker in DN.
Publish Date	2023-04-14 06:38
Citation	Dahiya K, Prashant P, Dhankhar R, Dhankhar K, Kumar S, Vashist S. Lipocalin-2 as a biomarker for diabetic nephropathy. World J Meta-Anal 2023; 11(4): 92-101
URL	https://www.wjgnet.com/2308-3840/full/v11/i4/92.htm
DOI	https://dx.doi.org/10.13105/wjma.v11.i4.92

Full Article (PDF)	WJMA-11-92.pdf
Full Article (Word)	WJMA-11-92.docx
Manuscript File	82569_Auto_Edited-LJH_WangTQ-JLW.docx
Answering Reviewers	82569-Answering reviewers.pdf
Audio Core Tip	82569-Audio core tip.mp4
Conflict-of-Interest Disclosure Form	82569-Conflict-of-interest statement.pdf
Copyright License Agreement	82569-Copyright license agreement.pdf
Peer-review Report	82569-Figure(s).pptx
Scientific Misconduct Check	82569-Bing-Liu JH-2.jpg
Scientific Misconduct Check	82569-CrossCheck.jpg
Scientific Editor Work List	82569-Scientific editor work list.pdf